Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)?
Gupta
R
R
World Health Organization.
Raviglione
M C
MC
Espinal
M A
MA
D000995:Antitubercular Agents / Q000627:therapeutic use*; D006078:Government Programs / Q000639:trends*; D006801:Humans; D007391:International Cooperation; D007538:Isoniazid / Q000627:therapeutic use*; D009313:National Health Programs / Q000639:trends*; D017410:Practice Guidelines as Topic; D012293:Rifampin / Q000627:therapeutic use*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014944:World Health Organization
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin